tag:www.gov.uk,2005:/government/organisations/advisory-council-on-the-misuse-of-drugsAdvisory Council on the Misuse of Drugs - Activity on 188ΜεΣύHM Government2025-03-12T12:00:02Z/government/publications/acmd-work-programme-2025#2025-03-12T12:00:02Z2025-03-12T12:00:02ZCorrespondence: ACMD work programme 2025Letter to the Home Secretary from the Chair of the Advisory Council on the Misuse of Drugs (ACMD) discussing the ACMD work programme for 2025./government/publications/synthetic-cathinones-an-updated-harms-assessment#2025-02-12T17:13:30Z2025-02-12T17:13:30ZResearch: Synthetic cathinones: an updated harms assessmentACMD has written an updated harms assessment describing the use and harms of synthetic cathinones following a government commission./government/publications/advisory-council-on-the-misuse-of-drugs-member-biographies#2025-02-10T13:12:02Z2025-02-10T13:12:02ZTransparency data: Advisory Council on the Misuse of Drugs member biographiesBiographies of members of the Advisory Council on the Misuse of Drugs./government/news/acmd-appoints-new-members#2025-02-10T12:52:27Z2025-02-10T12:52:27ZACMD appoints new membersFour more experts have been appointed members to the Advisory Council on the Misuse of Drugs./government/publications/members-register-of-interests#2025-02-10T12:45:17Z2025-02-10T12:45:17ZCorporate report: ACMD members' register of interestsOccupations, career history and interests of the members of the Advisory Council on the Misuse of Drugs (ACMD)./government/publications/acmd-advice-on-2-benzyl-benzimidazole-and-piperidine-benzimidazolone-opioids#2025-01-29T16:04:55Z2025-01-29T16:04:55ZResearch: ACMD advice on 2-benzyl benzimidazole and piperidine benzimidazolone opioidsA review of the evidence on the use and harms of 2-benzyl benzimidazole (nitazene) and piperidine benzimidazolone (brorphine-like) opioids./government/publications/updated-harms-assessment-of-ketamine-commissioning-letter#2025-01-16T07:58:29Z2025-01-16T07:58:29ZCorrespondence: Updated harms assessment of ketamine: commissioning letterThe government commissions the Advisory Council on the Misuse of Drugs (ACMD) to conduct an updated harms assessment of ketamine./government/news/acmd-appoints-10-leading-experts#2025-01-13T00:00:00Z2025-01-13T00:00:00ZACMD appoints 10 leading expertsTen leading experts have joined the Advisory Council on the Misuse of Drugs (ACMD) to strengthen its vital work advising the government on drug harms./government/publications/standard-operating-procedure-for-using-evidence-in-acmd-reports#2025-01-03T12:00:02Z2025-01-03T12:00:02ZCorporate report: Standard Operating Procedure for using evidence in ACMD reportsA document developed by the Advisory Council on the Misuse of Drugs (ACMD) to outline the governing process for preparing evidence-based advice./government/publications/acmd-annual-report-2020-to-2022#2024-12-20T12:00:00Z2024-12-20T12:00:00ZCorporate report: ACMD annual report 2020 to 2022Overview of the Advisory Council on the Misuse of Drugs' (ACMD) work from January 2020 to December 2022./government/publications/acmd-advice-on-reform-to-hemp-licensing-fees#2024-10-23T13:53:47Z2024-10-23T13:53:47ZCorrespondence: ACMD advice on reform to hemp licensing feesThe Advisory Council on the Misuse of Drugs responds to the government on their proposal to amend the licensing regimen for industrial hemp./government/publications/alkyl-nitrites-acmd-exemption-consideration#2024-08-09T12:34:19Z2024-08-09T12:34:19ZResearch: Alkyl nitrites: ACMD exemption considerationThe Advisory Council on the Misuse of Drugs has provided an updated harms assessment of alkyl nitrites. /government/calls-for-evidence/synthetic-cathinones#2024-05-20T11:00:00Z2024-05-20T11:00:00ZSynthetic cathinonesThe Novel Psychoactive Substances Committee (NPSC) is seeking evidence for its review of the evidence of the misuse and harms of synthetic cathinones in the UK. /government/publications/government-response-to-the-acmds-report-on-novel-benzodiazepines#2024-05-14T11:00:02Z2024-05-14T11:00:02ZCorrespondence: Government response to the ACMD's report on novel benzodiazepinesThe government responds to the ACMD's report on recently encountered novel benzodiazepines and related compounds./government/publications/government-response-to-acmd-report-on-acyl-piperazine-opioids#2024-05-14T11:00:02Z2024-05-14T11:00:02ZCorrespondence: Government response to ACMD report on acyl piperazine opioidsGovernment response to the report by the Advisory Council on the Misuse of Drugs on acyl piperazine opioids, including 2-methyl-AP-237./government/publications/reform-to-the-fees-applicable-under-the-hemp-licensing-regime#2024-04-09T11:00:08Z2024-04-09T11:00:08ZCorrespondence: Reform to the fees applicable under the hemp licensing regimeThe government commissions the Advisory Council on the Misuse of Drugs (ACMD) to review the fees applicable under the hemp licensing regime./government/publications/acmd-work-programme-2024#2024-04-05T11:00:13Z2024-04-05T11:00:13ZCorrespondence: ACMD work programme 2024ACMD work programme 2024 letter to the Home Secretary from the Chair of the Advisory Council on the Misuse of Drugs (ACMD)./government/publications/uncontrolled-novel-benzodiazepines-2024-update#2024-03-28T00:00:00Z2024-03-28T00:00:00ZResearch: Uncontrolled novel benzodiazepines: 2024 updateA review of the evidence on the use, harms and prevalence of recently encountered uncontrolled novel benzodiazepines and related compounds (2024 update)./government/publications/acmd-advice-on-acyl-piperazine-opioids-including-2-methyl-ap-237#2024-03-27T00:00:00Z2024-03-27T00:00:00ZResearch: ACMD advice on acyl piperazine opioids, including 2-methyl-AP-237This report has considered the harms and control of 2-methyl-AP-237 and other closely related acyl piperazine opioids./government/publications/response-to-the-acmds-report-on-xylazine-and-related-compounds#2024-03-21T14:15:00Z2024-03-21T14:15:00ZCorrespondence: Response to the ACMD's report on xylazine and related compoundsGovernment response to the report by the Advisory Council on the Misuse of Drugs on xylazine, medetomidine and detomidine.